Académique Documents
Professionnel Documents
Culture Documents
XENOBIOTIC
METABOLISM
INTRODUCTION TO XENOBIOTICS
Xenobiotic
Excretion
DETECTION OF TOXIC BURDEN
• Ammonia burden
• Citrate, isocitrate, cis-aconitate
• Orotate
• 8-OH-dG
• p-hydroxyphenyllactate
• 2-Methylhippurate
• Dysbiosis markers
ADDITIONAL MARKERS OF
TOXICANT EXPOSURE
• Urinary glucarate
• Phase I and II upregulation
• herbicide, fungicide, petrochemical, alcohol and drug exposure
• Urinary benzoate
• Glycine conjugation
DETECTION OF TOXIC BURDEN
• Porphyrins
• Heavy Metals
• Whole blood, RBC, serum
• Urine
• Hair
HOW XENOBIOTICS CAUSE TOXICITY
• Phase I:
• primarily cytochromes
• addition of functional groups
• Phase II:
• conjugation reactions
• attaches a water-soluble moiety
• Phase III:
• antiporter system
Phase I Nutrients: Antioxidants: Phase II Nutrients:
B vitamins Phytonutrients Glycine
Glutathione Vitamin C, E NAC
Flavanoids Minerals B vitamins
Phase I Phase II
Toxins (Cytochrome P450) Intermediate (Conjugation Pathways)
Excretion:
Reactions: Oxidation Metabolite Sulfation
Blood
Amino Acid conjugation
Urine
Glucronidation
Feces
Glutathione
Metnhylation
Free ROS
Radicals
Cell damage
PHASE I
12
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
13
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
14
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
15
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
16
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
17
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
18
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
19
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
20
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
21
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
22
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
23
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
24
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
25
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
26
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
27
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
28
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
29
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
30
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
31
(contin
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
ued)
32
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
33
Phase I metabolism - CYP Introduction to Pharmacology Octobe 4, 2007
34
PHASE I - CYP LIVER ENZYMES
Cyp2E1 6% Ethanol,
Carbon tetrachloride
Cyp2A6 4% Coumarin
PHASE II
• Mono-functional inducers
These elevate Phase II enzymes (such as glutathione S-transferases, NAD(P)H:quinone reductase,
UDP-glucuronosyl-transferases) in various tissues without significantly raising the Phase I
enzyme
Examples: cigarettes, charred meats, glucocorticoids,
• Bi-functional inducers
These induce both Phase I and Phase II enzymes
of xenobiotic metabolism.
Examples: flavonoids, garlic, rosemary, soy, cabbage, polycyclic
aromatic hydrocarbons
USE OF CHALLENGE COMPOUNDS TO
EVALUATE PHASES OF
DETOXIFICATION
CAFFEINE CLEARANCE
• 200 mg dose
• 2 and 8 hour saliva collection
• Phase I microsomal P450 mixed function oxidase activity
CAFFEINE CLEARANCE
If High:
• Liver is actively removing caffeine
• Enzyme induction
• Minimize exposure to environmental toxins
If Low:
• Genetic polymorphisms or loss of liver function
• Processing and degradation of foreign compounds is slower
than normal
• Xenobiotics could accumulate in adipose tissue
• Drugs: cimetidine, amphetamines, grapefruit (narengenin)
• Low exposure to toxins
ACETOMINOPHEN
BIOTRANSFORMATION
• 650 mg dose
• Urinary acetaminophen sulfate and acetaminophen
glucuronide
• Sulfate and B-vitamin status
ASPIRIN BIOTRANSFORMATION
• 650 mg dose
• O-hydroxyhippurate
• Glycine, pantothenic acid status
CONJUGATION PATHWAYS USED FOR
SPECIFIC COMPOUNDS
PHASE I/II RATIOS
• Bioactivation
• Impairment in phase II conjugation could lead to
accumulation of toxic intermediates
• Supplement with antioxidant nutrients
• Free radicals
• Cell injury
• DNA modification
• Haptens
FACTORS THAT INFLUENCE
DETOXIFICATION:
• Age
• Gender
• Diet and Lifestyle
• Environment
• Disease State
• Genetic polymorphisms
• Supplement use
• Intestinal Health
SUPPORTING DETOXIFICATION
• Antioxidants/protective nutrients
• vitamin C and E, zinc, lipoic acid
• Example of effects;
Felton, J.S. What do diet-induced changes in phase I and
phase II enzymes tell us about prevetnion from exposure
to heterocyclic amines? Journal of Nutrition, Oct 2006.
136(10); 2683-4S
http://jn.nutrition.org/cgi/content/full/136/10/2683S